Fecal Microbiota Transplantation (FMT) to Slow Biological Aging (LONGEVIBIOME)
A Randomized, Double-blind, Placebo-controlled Research Study Evaluating the Efficacy and Safety of Multi-dose Fecal Microbiota Transplantation (FMT) in Capsule Form as an Intervention to Slow Down the Rate of Biological Aging.
The goal of this clinical trial is to evaluate if multi-dose fecal microbiota transplantation (FMT) capsules can safely and effectively slow down biological aging and reduce chronic low-grade inflammation in adults aged 45 to 80 with metabolic neglect.
The main questions it aims to answer are:
- Can oral FMT capsules significantly slow the biological pace of aging as measured by the DunedinPACE epigenetic clock?
- Can FMT successfully reduce chronic systemic inflammation (measured by markers such as suPAR, IL-6, and hs-CRP)?
Researchers will compare participants receiving the active product to those receiving a matching placebo to see if the microbiome intervention improves metabolic health and cognitive function via the gut-brain axis.
Participants will:
- Undergo a short-term preparation phase involving targeted antibiotics and standard bowel cleansing.
- Receive an 2 initial induction doses of active product (or placebo) followed by 5 regular booster cycles administered approximately every 4 weeks.
- Attend periodic clinical visits for physical examinations, blood draws, stool sample collection (at home), and cognitive testing using the CANTAB platform and MoCA scale.
- Maintain a participant diary to record adverse events (AE), product administration, stool sample collection, and dietary habits.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntary written informed consent signed prior to any study-related procedures.
- Age between 45 and 80 years (inclusive) at the time of screening.
- Classified as "metabolically neglected" with documented pre-disease conditions or regulated early-stage chronic disorders.
- Accelerated biological aging rate 1.1, OR between 1.05 and 1.099 combined with chronic low-grade inflammation (inflammaging).
- Preserved cognitive function with a Montreal Cognitive Assessment (MoCA) score between 24 and 30 points.
- Physical ability to perform computerized cognitive tests on a touch-screen tablet.
- Commitment to maintaining stable dietary and physical activity habits throughout the study period.
- Possession of a home freezer and ability to strictly comply with cold-chain storage logistics for investigational products and stool samples.
- Demonstrated ability to swallow large capsules.
- Adequate baseline laboratory parameters (such as blood counts and kidney function).
- For women of childbearing potential: agreement to use a highly effective method of contraception throughout the study and for 30 days post-intervention.
- Readiness to ensure presence at the registered home address to receive scheduled frozen-chain courier shipments.
Exclusion Criteria:
- Systemic antibiotic therapy within 12 weeks prior to baseline.
- Supplementation with any commercial pre- or probiotics within 4 weeks prior to baseline.
- Diagnosed malignancy within the past 5 years (except fully cured basal cell carcinoma or cervical cancer in situ).
- Participation in any other clinical study or trial within 30 days prior to consent or during this study.
- Pregnancy, breastfeeding, or planning a pregnancy during the study and for 30 days post-intervention.
- Known hypersensitivity, intolerance, or allergy to any component of the investigational product (MBiotix HBI Caps), placebo, preparation antibiotics (Neomycin, Metronidazole), antibiotic placebo, or bowel cleansing solution (macrogols).
- Pre-existing hearing loss, chronic tinnitus, or diagnosed vestibular disorder. History of or active peripheral neuropathy of any etiology.
- Myasthenia gravis or other neuromuscular transmission disorders.
- Concurrent, ongoing use of loop diuretics, other aminoglycoside antibiotics, or known nephrotoxic drugs.
- Severe, unstable, or uncontrolled comorbidities, including NYHA Class III/IV heart failure, unstable angina, or myocardial infarction within the past 6 months.
- Severe hepatic impairment (Child-Pugh Class C) or severe renal impairment (eGFR < 30 mL/min/1.73 m²).
- Active, severe psychiatric disorders (e.g., severe depression with active suicidal ideation, psychotic disorders, unstable bipolar disorder).
Diagnosis of progressive neurodegenerative diseases (Parkinson's, Alzheimer's) or moderate-to-advanced dementia.
- Active, clinically significant inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other severe gastrointestinal disorders.
- Evidence of gastrointestinal mucosal damage (ulceration, perforation, bleeding) within 7 days prior to the first product dose.
- Clinically significant immunosuppression, including chronic systemic corticosteroids, HIV infection with a CD4+ cell count < 200/µl, history of solid organ or hematopoietic stem cell transplantation.
- Active infection requiring antibiotics during the induction phase or anticipated antibiotic use during the first 7 days post-induction.
- Prior fecal microbiota transplantation (FMT) treatment for indications other than recurrent C. difficile infection.
- Significant dysphagia precluding safe capsule ingestion.
- Inadequate baseline laboratory parameters (such as blood counts and kidney function).
- Any medical condition or circumstance judged by the Principal Investigator to compromise participant safety or protocol adherence.
- Anticipated inability to comply with study procedures, such as missing scheduled follow-up visits, lacking reliable home freezer storage, or having a lifestyle/occupation that prevents proper cold-chain product handling or consistent attendance.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:MBiotix HBI Caps
MBiotix HBI Caps (FMT capsules) + Preparation antibiotics (Neomycin and Metronidazole) + Standard bowel cleansing (Macrogols). Participants receive targeted preparation antibiotics followed by bowel cleansing, and then a multi-dose regimen of fecal microbiota transplantation (FMT) capsules (MBiotix HBI Caps) in an initial induction phase and subsequent booster cycles. |
Fecal microbiota transplantation (FMT) capsules administered in an initial induction phase followed by subsequent booster cycles. Frozen oral capsules containing full-spectrum human gut microbiota given as an initial induction (comprising a single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks. |
|
プラセボコンパレーター:Placebo
Placebo Capsules (matching MBiotix HBI Caps) + Antibiotics Placebo (matching two active antibiotics) + Standard bowel cleansing (Macrogols). Participants receive matching placebo treatments for both the preparation antibiotics and the oral capsules (MBiotix HBI placebo), along with the same standard bowel cleansing and multi-dose schedule (an initial induction phase and subsequent booster cycles). |
Placebo Capsules (Comparator): Frozen oral capsules identical in appearance, packaging, and dosing schedule to the active product, containing pharmacologically inert substances. Administered as an initial induction phase (single dose on Day 7 and split daily doses on Days 9-14) following preparation, followed by intermittent 6-day booster cycles administered approximately every 4 weeks |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Clinical and Biological Response (Responder Rate)
時間枠:Baseline, Week 13, and Week 26
|
The primary outcome is the proportion of participants categorized as "Responders" following multi-dose fecal microbiota transplantation (MBiotix HBI Caps) compared to placebo. A participant is classified as a Responder if they demonstrate objective physiological improvement from Baseline to Week 13 and/or Week 26, defined as meeting at least one of the following two pre-specified criteria:
Results will be reported as the percentage of participants in each treatment arm meeting this composite response definition. |
Baseline, Week 13, and Week 26
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 13/HBI/2026
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。